SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549
Form 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
September 17, 2003 (Date of earliest event reported)
Commission File Number 000-19627

BIOLASE TECHNOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

Delaware (State or Other Jurisdiction of Incorporation

000-19627 (Commission file

87-0442441 (I.R.S. Employer Identification No.)

or Organization)

number)

Edgar Filing: BIOLASE TECHNOLOGY INC - Form 8-K

981 Calle Amanecer

San Clemente, California 92673

(Address of Principal Executive Offices, Including Zip Code)

(949) 361-1200

(Registrant s Telephone Number, Including Area Code)

Edgar Filing: BIOLASE TECHNOLOGY INC - Form 8-K

Item 7. Financial Statements and Exhibits.

- (c) Exhibits.
- 99.1 Press Release, dated September 17, 2003.

Item 12. Results of Operations and Financial Condition.

On September 17, 2003, BioLase Technology, Inc. issued a press release announcing that it filed an amended 10-K and amended 10-Q s to restate financial statements for periods to account for differences in revenue recognition. A copy of the press release is attached herewith as Exhibit 99.1.

Edgar Filing: BIOLASE TECHNOLOGY INC - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 17, 2003 BIOLASE TECHNOLOGY, INC.,

(Registrant)

By: /s/ EDSON J. ROOD

Edson J. Rood

Vice President and

Chief Financial Officer

(Principal Financial and

Accounting Officer)